Pegcetacoplan Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 54 mg/mL, 15 mg/mL
Reference Brands: Empaveli (USA/EU), Syfovre(USA/EU)
Category:
Opthalmology
Pegcetacoplan is a targeted complement inhibitor that binds to complement protein C3, preventing its cleavage and downstream inflammatory effects. It is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy secondary to age-related macular degeneration (AMD). It helps reduce red blood cell destruction and slow retinal damage progression.
Pegcetacoplan is available in Injection
and strengths such as 54 mg/mL, 15 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pegcetacoplan is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pegcetacoplan can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pegcetacoplan is a pegylated peptide inhibitor that targets human complement components C3 and C3b, playing an important role in the treatment of diseases driven by excessive complement activation. By selectively binding to C3 and C3b, pegcetacoplan blocks the activation of the complement pathway, helping to reduce complement-mediated inflammation and cell destruction. This mechanism is particularly important in conditions where the immune system damages healthy cells and tissues.
Pegcetacoplan is primarily used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder characterized by the destruction of red blood cells. It is also approved in certain regions for the treatment of geographic atrophy associated with age-related macular degeneration. In addition, pegcetacoplan is being studied or used in conditions such as cold agglutinin disease and C3 glomerulopathy, where complement system dysregulation contributes to disease progression.
By targeting C3, a central component of the complement system and an essential part of the innate immune response, pegcetacoplan helps control abnormal immune activity and prevent tissue damage. This targeted approach provides a valuable therapeutic option for patients with complement-mediated disorders and related inflammatory diseases.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing